Please assess the completion status of the following clinical trial:

Trial Title: Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject fulfils criteria for Rheumatoid Arthritis (RA) according to ACR or EULAR criteria.~* Subjects who are planned to start treatment with ADA, ETA, CER or IFX~* Subjects taking a minimum weekly dose of 7.5 mg of methotrexate~Exclusion Criteria:~* Patients with compliance problems~* Patients who have difficulties in reading and understanding local language~* Patients with Juvenile Idiopathic Arthritis (JIA)~* Azathioprine or cyclophosphamide treatment within 6 months before entering into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adalimumab (Type: None): None
- Etanercept (Type: None): None
- infliximab (Type: None): None
- Certolizumab (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).